Skip to Content
Merck

Development of sulfonamide AKT PH domain inhibitors.

Bioorganic & medicinal chemistry (2011-03-01)
Ali Md Ahad, Song Zuohe, Lei Du-Cuny, Sylvestor A Moses, Li Li Zhou, Shuxing Zhang, Garth Powis, Emmanuelle J Meuillet, Eugene A Mash
ABSTRACT

Disruption of the phosphatidylinositol 3-kinase/AKT signaling pathway can lead to apoptosis in cancer cells. Previously we identified a lead sulfonamide that selectively bound to the pleckstrin homology (PH) domain of AKT and induced apoptosis when present at low micromolar concentrations. To examine the effects of structural modification, a set of sulfonamides related to the lead compound was designed, synthesized, and tested for binding to the expressed PH domain of AKT using a surface plasmon resonance-based competitive binding assay. Cellular activity was determined by means of an assay for pAKT production and a cell killing assay using BxPC-3 cells. The most active compounds in the set are lipophilic and possess an aliphatic chain of the proper length. Results were interpreted with the aid of computational modeling. This paper represents the first structure-activity relationship (SAR) study of a large family of AKT PH domain inhibitors. Information obtained will be used in the design of the next generation of inhibitors of AKT PH domain function.

MATERIALS
Product Number
Brand
Product Description

Supelco
Sulfamethizole, analytical standard, ≥99% (HPLC)
SKU
Pack Size
Availability
Price
Quantity
Supelco
Sulfamethizole, VETRANAL®, analytical standard
SKU
Pack Size
Availability
Price
Quantity